Patents by Inventor Junliang HAO

Junliang HAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators
    Publication number: 20230382869
    Abstract: The invention provides certain (phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one related compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, to treat certain symptoms of dopaminergic CNS disorders including Parkinson's disease, Schizophrenia, ADHD or Alzheimer's disease.
    Type: Application
    Filed: October 5, 2021
    Publication date: November 30, 2023
    Inventors: Junliang HAO, Richard D. JOHNSTON, Gregory Lawrence LACKNER, Erik J. HEMBRE, Kjell A. SVENSSON
  • 2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS
    Publication number: 20230167087
    Abstract: The present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula (I) for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
    Type: Application
    Filed: February 4, 2021
    Publication date: June 1, 2023
    Inventors: Timothy Barrett DURHAM, Junliang HAO, Richard Duane JOHNSTON
  • Dopamine D1 receptor positive allosteric modulators
    Patent number: 10611751
    Abstract: The invention provides certain (phenyl)-(pyrazol)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, or a pharmaceutically acceptable salt thereof, to treat certain symptoms of Parkinson's disease, schizophrenia, ADHD or Alzheimer's disease.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: April 7, 2020
    Assignee: Eli Lilly and Company
    Inventors: Darryl Wayne Hilliard, Junliang Hao, David Andrew Coates
  • DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
    Publication number: 20190322639
    Abstract: The invention provides certain (phenyl)-(pyrazol)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, or a pharmaceutically acceptable salt thereof, to treat certain symptoms of Parkinson's disease, schizophrenia, ADHD or Alzheimer's disease.
    Type: Application
    Filed: April 17, 2019
    Publication date: October 24, 2019
    Inventors: Darryl Wayne Hilliard, Junliang Hao, David Andrew Coates
  • 3,4-dihydroisoquinolin-2(1)-yl compounds
    Patent number: 8962654
    Abstract: The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: February 24, 2015
    Assignee: Eli Lilly and Company
    Inventors: Christopher David Beadle, David Andrew Coates, Junliang Hao, Joseph Herman Krushinski, Jr., Matthew Robert Reinhard, John Mehnert Schaus, Craig Daniel Wolfangel
  • 3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS
    Publication number: 20140357664
    Abstract: The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia.
    Type: Application
    Filed: May 27, 2014
    Publication date: December 4, 2014
    Applicant: Eli Lilly and Company
    Inventors: Christopher David BEADLE, David Andrew COATES, Junliang HAO, Joseph Herman KRUSHINSKI, JR., Matthew Robert REINHARD, John Mehnert SCHAUS, Craig Daniel WOLFANGEL